undamentalytics Newsletter
Sign in

Biomerica Inc (BMRA) stock

Add to watchlist

Add holding +

NASDAQ: BMRA Nasdaq Health Care Equipment

D Fundamentals grade

Biomerica Inc is a US-listed company in the health care equipment industry. Its financial year ends in May.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$0.9

Price-to-sales vs peers

Base case. Range ~$0.9–$4.7. Sales per share times peers' typical price-to-sales; used only when earnings are negative.

Price vs value

No Buy/Hold/Sell rating is issued: only 1 valuation models apply; a rating needs 3.

Biomerica Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders5 buying, 0 selling5 purchases and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds10 adding, 2 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Biomerica files

Where Biomerica stands after its latest 10-Q

Biomerica has little or no product revenue yet; it used $4m of cash in the twelve months to August 2026. That puts it 94 of 103 for growth among the health care equipment companies we cover. The diluted share count is up 26.7% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 2 financial-health checks. Our price-to-sales vs peers value is $1.28 a share, against a share price of $1.74.

Source: 10-Q filed October 15, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Biomerica Inc's trailing-twelve-month revenue fell 11.2% year on year, with a free-cash-flow margin of -91.2%. Where it stands out: change in growth rate of +5.0pp ranks 24 of 129 health care equipment companies we cover. Where it lags: gross margin of 0.9% ranks 117 of 123 health care equipment companies we cover.

Current signal Revenue growth accelerating: TTM revenue growth rose to -11.2% (+5.0pp vs the prior quarter).

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Revenue shrinking. Revenue fell 11.2% over the last 12 months.
  • Loss-making. Operating margin is -125.2%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 25.2 points on a year ago.
  • Burning cash. Free cash flow was -91.2% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 26.7% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 58% and a beta of 0.7 against the S&P 500.

Latest results: FY2027 Q1

Filed October 15, 2026
Revenue
$1m, down 8.3% on a year earlier

Biomerica's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day0.0%
  • 1 week+1.2%
  • 1 month-19.2%
  • This year-31.3%
  • 1 year-36.2%
  • 5 years-95.1%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$4.3M
Operating margin
-125.2%
Net margin
-115.5%
EPS (TTM, diluted)
$-1.63

Growth

Revenue growth
−11.2%
Change in growth rate
+5.0 pts
Share count change
+26.7%

Cash

Free cash flow (TTM)
-$4M
FCF margin
-91.2%
Stock pay % of revenue
8.2%

Earnings

Last results
December 16, 2021

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biomerica Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: only 1 valuation models apply; a rating needs 3.

Valuation models

We value Biomerica Inc as an operating company, with every model that fits that kind of business. Cost of equity 10.6%: the 10-year Treasury yield (4.9%) plus a beta of 1.26 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: revenue and margins don't support a positive value
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. ~$0.9 ~$1.1–$4.7 Included, half weight
Combined value Weighted average of the models that apply: the primary model (revenue-to-maturity model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$0.9 ~$0.9–$4.7 1 model

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biomerica Inc with Health Care Equipment in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 20162017201820192020202120222023202420252026Now
Share price$12.80$20.00$32.56$18.00$51.76$29.20$28.00$10.96$4.64$3.05$2.39$1.73
Market value$12m$21m$35m$21m$66m$44m$44m$19m$10m$7m$7m$5m
+ Net debt (− = net cash)−$2m−$1m−$1m−$686785−$9m−$4m−$6m−$10m−$4m−$2m−$1m−$3m
Enterprise value$10m$20m$34m$20m$57m$39m$38m$10m$6m$5m$6m$3m
Multiples
Price / sales 2.4x3.6x6.3x4.0x9.8x6.0x2.4x3.6x1.8x1.3x1.6x1.2x
Price / earnings ————————————
Price / free cash flow ————————————
EV / EBITDA ————————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

10 /100

Weak moat

How hard Biomerica's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -29.8% of total assets over 10 years.

  • Pricing power 0 / 20

    Gross margin has been a median 16.3%, moving by 10.5 percentage points (standard deviation) across 10 years.

  • Durability 10 / 20

    Operating margin has been a median -79.9%; its worst year was -125.2%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -53.5% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 130.9% over five years; stock-based pay has been a median 11.7% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

No analyst estimates are published for Biomerica Inc: too few analysts cover it.

Management guidance

Earnings release, December 16, 2021

No numeric guidance in Biomerica Inc's latest earnings release (filed December 16, 2021). Some companies give their outlook only on the earnings call.

Positioning

Short interest
0.3%
of tradable shares
Days to cover
0.45
at average volume
Short interest, 1 month
−72%
to October 15, 2026
Held by institutions
3%
of shares
Held by insiders
21.9%
of shares
Employees
50
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −38.0%

$2.79 on October 31, 2025 to $1.73

ThenNowEffect
Revenue (last 12 months) $5m $4m −11.2%
P/S multiple 1.4x 1.2x −11.6%
Share count 2m 3m −21.1%

Biggest factor: share count. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BMRA−22%−14%−63%−76%+5%−31%
Industry peers (median)−7%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BMRA50%50%25%33%42%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BMRA−57%−44%−80%−79%−74%−48%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 99% from March 19, 2020 to July 31, 2026. Getting back needed a 8491% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.49 – $2.88
From 52-week high
−39.9%
vs 50-day average
−16.3%
vs 200-day average
−15.3%
Volatility (1 year)
58%
Beta vs S&P 500
0.73

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
1 up, 0 down
typical move ±3.2%
After a week
1 up, 0 down
typical move ±3.4%
After a month
1 up, 0 down
typical move ±11.1%
Results releasedNext dayS&P 500 next day5 days21 days
December 16, 2021 +3.2% −1.9% +3.4% +11.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Biomerica Inc in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Biomerica Inc
$4M $4.5M $5M $5.5M $6M FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue (TTM), FY24 Q2: $5.5M Revenue (TTM), FY24 Q3: $5.4M Revenue (TTM), FY24 Q4: $5.4M Revenue (TTM), FY25 Q1: $5.5M Revenue (TTM), FY25 Q2: $5.6M Revenue (TTM), FY25 Q3: $5.7M Revenue (TTM), FY25 Q4: $5.3M Revenue (TTM), FY26 Q1: $4.9M Revenue (TTM), FY26 Q2: $4.5M Revenue (TTM), FY26 Q3: $4.3M Revenue (TTM), FY26 Q4: $4.5M Revenue (TTM), FY27 Q1: $4.3M $4.3M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY24 Q2 $5.5M
FY24 Q3 $5.4M
FY24 Q4 $5.4M
FY25 Q1 $5.5M
FY25 Q2 $5.6M
FY25 Q3 $5.7M
FY25 Q4 $5.3M
FY26 Q1 $4.9M
FY26 Q2 $4.5M
FY26 Q3 $4.3M
FY26 Q4 $4.5M
FY27 Q1 $4.3M
Revenue growth, TTM YoY Biomerica Inc
-80% -60% -40% -20% 0% 20% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Revenue growth, TTM YoY, FY24 Q2: -65.8% Revenue growth, TTM YoY, FY24 Q3: -43.3% Revenue growth, TTM YoY, FY24 Q4: 1.4% Revenue growth, TTM YoY, FY25 Q1: 1.7% Revenue growth, TTM YoY, FY25 Q2: 1.4% Revenue growth, TTM YoY, FY25 Q3: 5.1% Revenue growth, TTM YoY, FY25 Q4: -1.9% Revenue growth, TTM YoY, FY26 Q1: -11.3% Revenue growth, TTM YoY, FY26 Q2: -20.1% Revenue growth, TTM YoY, FY26 Q3: -23.8% Revenue growth, TTM YoY, FY26 Q4: -16.2% Revenue growth, TTM YoY, FY27 Q1: -11.2% -11.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q2 -65.8%
FY24 Q3 -43.3%
FY24 Q4 1.4%
FY25 Q1 1.7%
FY25 Q2 1.4%
FY25 Q3 5.1%
FY25 Q4 -1.9%
FY26 Q1 -11.3%
FY26 Q2 -20.1%
FY26 Q3 -23.8%
FY26 Q4 -16.2%
FY27 Q1 -11.2%
Operating margin (TTM) Biomerica Inc
-150% -100% -50% 0% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 Operating margin (TTM), FY24 Q2: -115.1% Operating margin (TTM), FY24 Q3: -123.5% Operating margin (TTM), FY24 Q4: -117.6% Operating margin (TTM), FY25 Q1: -118.1% Operating margin (TTM), FY25 Q2: -105.6% Operating margin (TTM), FY25 Q3: -89.8% Operating margin (TTM), FY25 Q4: -96.7% Operating margin (TTM), FY26 Q1: -100.0% Operating margin (TTM), FY26 Q2: -118.1% Operating margin (TTM), FY26 Q3: -123.7% Operating margin (TTM), FY26 Q4: -119.5% Operating margin (TTM), FY27 Q1: -125.2% -125.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY24 Q2 -115.1%
FY24 Q3 -123.5%
FY24 Q4 -117.6%
FY25 Q1 -118.1%
FY25 Q2 -105.6%
FY25 Q3 -89.8%
FY25 Q4 -96.7%
FY26 Q1 -100.0%
FY26 Q2 -118.1%
FY26 Q3 -123.7%
FY26 Q4 -119.5%
FY27 Q1 -125.2%
FCF margin (TTM) Biomerica Inc
-100% -50% 0% FY24 Q2 FY25 Q1 FY25 Q4 FY27 Q1 FCF margin (TTM), FY24 Q2: -95.2% FCF margin (TTM), FY24 Q3: -98.2% FCF margin (TTM), FY24 Q4: -100.0% FCF margin (TTM), FY25 Q1: -91.4% FCF margin (TTM), FY25 Q2: -89.3% FCF margin (TTM), FY25 Q3: -74.4% FCF margin (TTM), FY25 Q4: -72.3% FCF margin (TTM), FY26 Q1: -56.6% FCF margin (TTM), FY26 Q2: -66.5% FCF margin (TTM), FY26 Q3: -73.3% FCF margin (TTM), FY26 Q4: -76.8% FCF margin (TTM), FY27 Q1: -91.2% -91.2%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY24 Q2 -95.2%
FY24 Q3 -98.2%
FY24 Q4 -100.0%
FY25 Q1 -91.4%
FY25 Q2 -89.3%
FY25 Q3 -74.4%
FY25 Q4 -72.3%
FY26 Q1 -56.6%
FY26 Q2 -66.5%
FY26 Q3 -73.3%
FY26 Q4 -76.8%
FY27 Q1 -91.2%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q, 10-Q/A. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2011 May 2011 2012 May 2012 2013 May 2013 2014 May 2014 2015 May 2015 2016 May 2016 2017 May 2017 2018 May 2018 2019 May 2019 2020 May 2020 2021 May 2021 2022 May 2022 2023 May 2023 2024 May 2024 2025 May 2025 2026 May 2026 LTM Aug 2026
Income
Revenue 5 6 6 5 5 5 6 6 5 7 7 19 5 5 5 4 4
Gross profit 2 2 2 2 2 2 2 2 1 2 0 3 0 1 0 0 0
EBITDA −0 1 1 −0 −0 −1 −1 −1 −2 −3 −7 −4 −7 −6 −5 −5 −5
Operating income −0 1 1 −0 −1 −1 −1 −1 −2 −3 −7 −5 −7 −6 −5 −5 −5
Net income 0 1 1 −0 −0 −1 −1 −1 −2 −3 −7 −5 −7 −6 −5 −4 −5
Diluted EPS $0.16 $0.64 $0.56 −$0.24 −$0.32 −$1.60 −$0.88 −$1.36 −$2.08 −$2.08 −$4.96 −$2.88 −$4.00 −$2.84 −$2.16 −$1.30 −$1.63
Growth (year on year)
Revenue — +24.1% +6.4% −20.9% −3.1% +3.6% +12.7% −3.9% −6.5% +28.7% +7.6% +162.1% −71.7% +1.4% −1.9% −16.2% −11.2%
EBITDA — — +7.5% −138.4% — — — — — — — — — — — — —
Operating income — — +1.8% −186.9% — — — — — — — — — — — — —
Net income — +248.3% −2.1% −140.2% — — — — — — — — — — — — —
Diluted EPS — +300.0% −12.5% −142.9% — — — — — — — — — — — — —
Margins
Gross margin 31.1% 37.8% 37.5% 32.6% 31.1% 29.7% 34.9% 31.5% 24.8% 26.0% 5.1% 15.8% 8.4% 11.3% 9.4% 8.1% 0.9%
EBITDA margin −0.0% 10.7% 10.8% −5.3% −9.9% −13.0% −14.0% −24.6% −44.4% −39.4% −102.7% −22.2% −133.7% −116.1% −95.1% −117.7% −123.6%
Operating margin −2.7% 8.3% 7.9% −8.7% −13.5% −16.1% −16.5% −26.6% −46.4% −41.0% −104.2% −24.0% −135.3% −117.6% −96.7% −119.5% −125.2%
Net margin 3.2% 9.0% 8.3% −4.2% −6.7% −29.2% −15.7% −26.3% −46.0% −40.0% −103.4% −24.0% −133.7% −110.4% −93.6% −84.8% −115.5%
Free-cash-flow margin 3.8% −0.3% 17.6% −19.5% −8.4% −5.8% −14.1% −23.4% −45.1% −64.7% −74.8% −2.8% −103.7% −99.9% −72.3% −76.8% −91.2%
Cash flow
Cash from operations 0 0 1 −1 −0 −0 −1 −1 −2 −4 −5 −0 −5 −5 −4 −3 −4
Capital spending 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Free cash flow 0 −0 1 −1 −0 −0 −1 −1 −2 −4 −5 −1 −6 −5 −4 −3 −4
Stock-based pay — — — — — — — 0 0 — 1 1 1 1 0 0 0
Free cash flow after stock pay — — — — — — — −1 −2 — −7 −2 −7 −6 −4 −4 −4
Balance sheet
Cash 1 1 2 2 1 2 1 1 1 9 4 6 10 4 2 1 3
Total debt 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −1 −1 −2 −2 −1 −2 −1 −1 −1 −9 −4 −6 −10 −4 −2 −1 −3
Diluted shares — — — — — — 1m 1m 1m 1m 1m 2m 2m 2m 2m 3m 3m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · August 31, 2026
What it owns · $8m
Short-term assets $5mLonger-term assets $3m
What it owes, and who funded it · $8m
Short-term liabilities $3mLonger-term liabilities $2mShareholders' equity $4m
  • Short-term assets cover short-term liabilities $5m of assets due within a year against $3m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $5m short-term assets against $2m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Biomerica Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+26.7%
year over year
R&D spending
18.0%
of revenue
Sales & admin spending
108.1%
of revenue
Days sales outstanding
75 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated BMRA INBS CNSY MCTA NRXS LUCD Median
Revenue, last 12 months $4m $4m $4m $5m $5m $5m $99m
Revenue growth, last 12 months −11.2% 38.1% −21.0% −22.7% 65.2% 24.9% 9.2%
Revenue growth, 3-year average −7.1% 39.0% 16.1% — 25.6% 90.1% 13.5%
Revenue growth, latest quarter −8.3% 178.9% −70.4% — 115.7% 26.7% 10.2%
Gross margin 0.9% 48.6% 15.1% 99.3% 85.6% 2.1% 61.2%
Operating margin −125.2% −297.8% −628.1% −0.6% −144.5% −930.9% −8.5%
Operating margin, 3-year average −114.4% −325.8% −383.3% — −249.7% <−999% −17.9%
Net margin −115.5% −294.9% −620.7% −0.5% −144.4% −959.8% −12.0%
Cash from operations / revenue −91.2% −283.0% −527.6% −25.3% −105.7% −860.8% −1.9%
Free-cash-flow margin −91.2% −285.9% −560.3% −32.4% −105.7% −876.8% −3.9%
Free-cash-flow margin, 3-year average −79.7% — −402.6% — −224.0% <−999% −7.0%
Stock pay / revenue 8.2% 4.3% 73.6% — 9.2% 101.4% 6.1%
Change in share count 26.7% 50.1% −99.4% 5.3% 43.8% 103.6% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth -11.2% 9.1% 114 of 129
Change in growth rate Growth +5.0pp -0.6pp 24 of 129
Gross margin Profitability 0.9% 61.9% 117 of 123
Operating margin Profitability -125.2% -8.3% 105 of 132
Net margin Profitability -115.5% -12.0% 104 of 133
Free-cash-flow margin Cash generation -91.2% -3.4% 103 of 128
Stock pay as % of revenue Cash generation 8.2% 6.1% 69 of 123
Change in share count Balance sheet 26.7% 3.3% 97 of 115
Days sales outstanding Balance sheet 75 days 57 days 90 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to May 31, 2026
Products and services
Line of business Revenue Share YoY
Clinical Lab $2.7M 61.4% ▼ 14.1%
Contract Manufacturing $891,000 20.0% ▼ 16.7%
Over The Counte $821,000 18.4% ▼ 21.7%
Physicians Office $9,000 0.2% ▼ 18.2%
Geography
Region Revenue Share YoY
North America $1.5M 32.9% ▼ 11.6%
Asia $1.4M 31.6% ▼ 18.0%
Europe $1.1M 25.1% ▼ 13.9%
Middle East $446,000 10.0% ▼ 29.2%
South America $15,000 0.3% ▲ 87.5%

From Biomerica Inc's 10-K filed August 31, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$219,990
Institutions reporting
20
Shares held vs prior quarter
▲ 12.1%
Positions opened / closed
9 / 0

Top buyers and sellers, Q2 2026: 10 institutions bought and 2 sold ; the biggest buyer was HRT Financial LP (+26K shares) and the biggest seller Geode Capital Management, LLC (−32K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
HRT Financial LP $46,000 26K 20.9% New
Geode Capital Management, LLC $42,857 24K 19.5% ▼ 56.6%
Blackrock, Inc. $32,799 19K 14.9% 0.0%
Vanguard Capital Management LLC $25,545 15K 11.6% 0.0%
Jane Street Group, LLC $22,246 13K 10.1% New
LPL Financial LLC $19,094 11K 8.7% 0.0%
UBS Group AG $12,234 7K 5.6% ▲ 1239.3%
Vanguard Fiduciary Trust Co $11,639 7K 5.3% 0.0%
Newedge Advisors, LLC $6,341 4K 2.9% 0.0%
Tower Research Capital LLC (TRC) $419 0K 0.2% New
Hollencrest Capital Management $352 0K 0.2% ▼ 75.8%
Harbour Investments, Inc. $220 0K 0.1% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biomerica Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $158,000 5 trades by 5 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $158,000 net buying
Insider Date Trade Shares Price Value
Irani Zackary S. Chief Executive Officer August 26, 2026 Buy 31,250 $1.60 $50,000
Barbieri Allen Executive Vice Chairman August 26, 2026 Buy 20,000 $1.60 $32,000
Chin Eric Director August 26, 2026 Buy 6,250 $1.60 $10,000
Moatazedi David Director August 26, 2026 Buy 10,000 $1.60 $16,000
Gary M. Huff Director August 20, 2026 Buy 31,250 $1.60 $50,000

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

  • December 16, 2021

Recent SEC filings

Data status

When each part of this page on Biomerica Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biomerica Inc in brief

What does Biomerica Inc do?
Biomerica Inc is a US-listed company in the health care equipment industry. Its financial year ends in May.
What is Biomerica Inc's stock ticker?
Biomerica Inc trades under the ticker BMRA on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biomerica Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biomerica Inc reported revenue of $4.3M, 11.2% lower than a year earlier, according to its SEC filings.
What is Biomerica Inc's free cash flow?
Biomerica Inc's free-cash-flow margin is -91.2% of revenue over the trailing twelve months, ranking 103 of the 128 health care equipment companies we cover.
Who are Biomerica Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are HRT Financial LP, Geode Capital Management, LLC and Blackrock, Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Biomerica Inc's market cap?
On November 2, 2026, Biomerica Inc's market capitalisation was about $5.3M and net debt of -$2.7M. Market figures come from third-party market data and may be delayed.
Who are Biomerica Inc's competitors?
In our Health Care Equipment peer group, the companies closest to Biomerica Inc are Intelligent BIO Solutions Inc., Cerenome, Inc., Charming Medical Ltd, Neuraxis, Inc and Lucid Diagnostics Inc. The side-by-side comparison below sets their revenue, margins and growth against Biomerica Inc's.
Are insiders buying or selling Biomerica Inc stock?
Over the last 12 months, Biomerica Inc's directors and officers reported 5 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.